Dr. Kutub Mahmood

As a seasoned leader with over 30 years of expertise in vaccine development, Dr. Mahmood brings industry and Global Health experience to Batavia Biosciences’ Scientific Advisory Board.

Kutub Mahmood, PhD, is currently working as PATH’s Scientific Director at the Center for Vaccines Innovation and Access (CVIA). He leads projects for polio vaccine development and scale-up for OPV, Sabin IPV (sIPV) and hexavalent vaccines. His other projects include work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines.

With Dr. Mahmood’s in-depth expertise, Batavia Biosciences strengthens its position as a frontrunner in vaccine development. With years of collaboration and research, Dr. Kutub Mahmood has developed an extensive global network that will be crucial in forming new partnerships and opportunities for Batavia Biosciences. This relationship enhances the company’s vaccine projects, leveraging Dr. Mahmood’s extensive experience and valuable insights.

Dr. Mahmood: “I have been continually impressed with Batavia’s deep scientific expertise in product development and contract manufacturing, which is at the core of its CDMO business in harnessing new low cost technologies for effective use in low and middle income countries. In the scientific advisory capacity, I have seen Batavia grown to expand in emerging diseases threat of pandemic potential and it will continue to play a pivotal role in new vaccines and biologicals development, contract development, manufacturing and technology transfer.

Kutub Mahmood

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression